Association Between HLA genotypes and Oxcarbazepine-induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-Analysis

被引:0
|
作者
Tangamornsuksan, Wimonchat [1 ,3 ]
Scholfield, C. N. [1 ,3 ]
Lohitnavy, Manupat [1 ,2 ,3 ]
机构
[1] Naresuan Univ, Fac Pharmaceut Sci, Ctr Excellence Environm Hlth & Toxicol, Phitsanulok, Thailand
[2] Naresuan Univ, Fac Pharmaceut Sci, Pharmacokinet Res Unit, Phitsanulok, Thailand
[3] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharm Practice, Phitsanulok, Thailand
来源
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES | 2018年 / 21卷
关键词
STEVENS-JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; RISK; ALLELE; HYPERSENSITIVITY; HLA-A-ASTERISK-31/01;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
PURPOSE: To systematically review and quantitatively synthesize associations between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions (OXC-cADRs), including Stevens-Johnson syndrome (SJS) and maculopapular rash. METHODS: Studies investigating associations between HLA genotypes and OXC-cADRs were systematically searched irrespective of language, in PubMed, HuGENet (Human Genome Epidemiology Network), and the Cochrane Library from their inception until January, 2017. Inclusion criteria were studies investigating associations between HLA genotypes and OXC-cADRs that reported sufficient data for calculating the frequency of HLA genotype carriers among cases and controls. Overall odds ratios (ORs) with corresponding 95% CIs were calculated using a random-effects model to determine the association between HLA genotypes and OXC-cADRs. RESULTS: The initial searches identified 91 articles, of which 6 studies met the selection criteria. The studies included 229 patients with OXC-cADRs, 251 OXC-tolerant patients, and 2,358 participants from general populations of Han Chinese, Korean, and Thai ethnicities. Associations between HLA-B*1502 and OXC-induced SJS were found in both the general population [OR=30.2 (95% CI=3.45-264)] and in OXC-tolerant individuals [OR=26.4 (95% CI=7.98-87.6)]. An association between the HLA-B*1502 and OXC-induced maculopapular rash was found in the general population [OR=5.67 (95% CI=2.03-15.9)] while HLA-A*3101 also associated with OXC-induced maculopapular rash [overall OR=29.2 (95% CI=6.70-128)]. CONCLUSIONS: Strong associations between the HLA-B*1502 and OXC-cADRs (SJS and maculopapular rash) were found in both controls from general population and OXC-tolerant groups. There was also an association between HLA-B*3101 and OXC-induced maculopapular rash. For patient safety, genetic screening especially for HLA-B*1502 prior to OXC therapy at least in these closely related ethnicities is warranted. Further studies need to better define other ethnicities at risk and a wider range of MHC gene subtypes.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 50 条
  • [41] HLA-B*58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
    Sukasem, Chonlaphat
    Jantararoungtong, Thawinee
    Kuntawong, Parnrat
    Puangpetch, Apichaya
    Koomdee, Napatrupron
    Satapornpong, Patompong
    Supapsophon, Patcharin
    Klaewsongkram, Jettanong
    Rerkpattanapipat, Ticha
    FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [42] HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis
    Grover, Sandeep
    Kukreti, Ritushree
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (02): : 94 - 112
  • [43] Association of autoimmune hepatitis and cutaneous malignancies: a systematic review and meta-analysis
    Tan, Marcus G.
    Bailey, Adrian Michel Joseph
    Toy, Jeffrey
    Tolkachjov, Stanislav N.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2023, 62 (11) : E576 - E578
  • [44] The association between bacteriuria and adverse pregnancy outcomes: a systematic review and meta-analysis of observational studies
    Piazzolla, Hans R. W.
    Modin, Frederikke
    Halkjaer, Sofie, I
    Petersen, Andreas M.
    Calum, Henrik
    Holm, Anne
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (02) : 241 - 254
  • [45] HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis
    Castro, Elena M. Cornejo
    Carr, Daniel F.
    Jorgensen, Andrea L.
    Alfirevic, Ana
    Pirmohamed, Munir
    PHARMACOGENETICS AND GENOMICS, 2015, 25 (04): : 186 - 198
  • [46] HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions
    Shi, Yi-Wu
    Min, Fu-Li
    Zhou, Dong
    Qin, Bin
    Wang, Juan
    Hu, Fa-Yun
    Cheung, Ying-Kit
    Zhou, Jin-Hua
    Hu, Xiang-Shu
    Zhou, Jue-Qian
    Zhou, Lie-Min
    Zheng, Zhong-zheng
    Pan, Jie
    He, Na
    Liu, Zhi-Sheng
    Hou, Yun-Qi
    Lim, Kheng-Seang
    Ou, Yang-mei
    Khor, Amy Hui-Ping
    Ng, Ching-Ching
    Mao, Bi-Jun
    Liu, Xiao-Rong
    Li, Bing-Mei
    Kuan, Yao-Yun
    Yi, Yong-Hong
    He, Xue-lian
    Deng, Xiao-Yan
    Su, Tao
    Kwan, Patrick
    Liao, Wei-Ping
    NEUROLOGY, 2017, 88 (23) : 2183 - 2191
  • [47] HLA-B Alleles and Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Han Chinese Population
    Shi, Yi-Wu
    Min, Fu-Li
    Liu, Xiao-Rong
    Zan, Li-Xuan
    Gao, Mei-Mei
    Yu, Mei-Juan
    Liao, Wei-Ping
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 (01) : 42 - 46
  • [48] Adverse fetal and neonatal outcomes following in-utero exposure to oxcarbazepine: A systematic review and meta-analysis
    Athar, Farwa
    Ehsan, Muhammad
    Farooq, Minaam
    Lo, Kevin B.
    Cheema, Huzaifa A.
    Ahmad, Shahzaib
    Naveed, Aiman
    Umer, Mohammad
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3600 - 3609
  • [49] Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population
    Chang, C-C
    Ng, C-C
    Too, C-L
    Choon, S-E
    Lees, C-K
    Chung, W-H
    Hussein, S. H.
    Lim, K-S
    Murad, S.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (02): : 170 - 173
  • [50] Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions
    Wattanachai, Pansakon
    Amornpinyo, Warayuwadee
    Konyoung, Parinya
    Purimart, Danklai
    Khunarkornsiri, Usanee
    Pattanacheewapull, Oranuch
    Tassaneeyakul, Wichittra
    Nakkam, Nontaya
    FRONTIERS IN PHARMACOLOGY, 2023, 14